The proteasome: A suitable antineoplastic target

Nature Reviews Cancer

Volumn 4, Issue 5, 2004, Pages 349-360

  Adams, Julian ^a  

^a Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 5 IODO 3 NITROPHENYLACETYLLEUCYLLEUCYLLEUCINAL VINYL SULFONE; ACLACINOMYCIN; ANTINEOPLASTIC AGENT; BENZAMIDE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CALPASTATIN; CASPASE; CELL PROTEIN; CVT 634; CYCLINE; DEXAMETHASONE; DOXORUBICIN; EPONEMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MELPHALAN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; RITONAVIR; UNCLASSIFIED DRUG;

ANEMIA; ANOREXIA; APOPTOSIS; ASTHENIA; CANCER CELL; CANCER THERAPY; CELL CYCLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG SELECTIVITY; DRUG TARGETING; EUKARYOTIC CELL; FATIGUE; FEVER; HUMAN; HYPOKALEMIA; HYPONATREMIA; MALAISE; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 2342613652     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1361     Document Type: Review

References (139)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Ciechanover, A. The ubiquitin-proteasome proteolytic pathway. Cell 79, 13-21 (1994).
3. Hough, R., Pratt, G. & Rechsteiner, M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J. Biol. Chem. 262, 8303-8313 (1987).
4. Waxman, L., Fagan, J. M. & Goldberg, A. L. Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates. J. Biol. Chem. 262, 2451-2457 (1987).
5. Bortezomib (Velcade) for multiple myeloma. Med. Lett. Drugs Ther. 45, 57-58 (2003).
6. Brooks, P. et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem. J. 346, 155-161 (2000). This paper demonstrates the complexity of proteasomal populations and localizations in mammalian cells.
7. Peters, J. M., Cejka, Z., Harris, J. R., Kleinschmidt, J. A. & Baumeister, W. Structural features of the 26 S proteasome complex. J. Mol. Biol. 234, 932-937 (1993).
8. Eliott, P. J. & Ross, J. S. The proteasome: a new target for novel drug therapies. Am. J. Clin. Pathol. 116, 837-646 (2001).
9. Baumeister, W., Walz, J., Zuhl, F. & Seemuller, E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367-380 (1998).
10. Ciechanover, A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17. 7151-7160 (1998).
11. DeMartino, G. N. & Slaughter, C. A. The proteasome, a novel protease regulated by multiple mechanisms. J. Biol. Chem. 274, 22123-22126 (1999).
12. Kisselev, A. F., Akopian, T. N., Castillo, V. & Goldberg, A. L. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell 4, 395-402 (1999).
13. Goldberg, A. L., Cascio, P., Saric, T. & Rock, K. L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39, 147-164 (2002).
14. Kisselev, A. F. et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem. 278, 35869-35877 (2003).
15. Glickman, M. H. et al. A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 94, 615-623 (1998).
16. Benaroudj, N., Zwickl, P., Seemuller, E., Baumeister, W. & Goldberg, A. L. ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation. Mol. Cell 11, 69-78 (2003).
17. Kalejta, R. F. & Shenk, T. Proteasome-dependent, ubiquitin-independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl Acad. Sci. USA 100, 3263-3268 (2003).
18. Benaroudj, N., Tarcsa, E., Cascio, P. & Goldberg, A. L. The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes. Biochimie 83, 311-318 (2001).
19. Ahn, K. et al. In vivo characterization of the proteasome regulator PA28. J. Biol. Chem. 271, 18237-18242 (1996).
20. Ma, C. P., Slaughter, C. A. & DeMartino, G. N. Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem. 267, 10515-10523 (1992).
21. Mott, J. D. et al. PA28, an activator of the 20 S proteasome, is composed of two nonidentical but homologous subunits. J. Biol. Chem. 269, 31466-31471 (1994).
22. Nikaido, T. et al. Cloning and nucleotide sequence of cDNA for Ki antigen, a highly conserved nuclear protein detected with sera from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 79, 209-214 (1990).
23. Realini, C. et al. Characterization of recombinant REGα, REGβ, and REGγ proteasome activators. J. Biol. Chem. 272, 25483-25492 (1997).
24. Rechsteiner, M., Realini, C. & Ustrell, V. The proteasome activator 11 S REG (PA28) and class I antigen presentation. Biochem. J. 345, 1-15 (2000).
25. Groettrup, M. et al. A role for the proteasome regulator PA28α in antigen presentation. Nature 381, 166-168 (1996).
26. Murata, S. et al. Immunoproteasome assembly and antigen presentation in mice lacking both PA28α and PA28β. EMBO J. 20, 5898-5907 (2001).
27. Gaczynska, M., Rock, K. L. & Goldberg, A. L. γ-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264-267 (1993).
28. Bose, S., Brooks, P., Mason, G. G. & Rivett, A. J. γ-interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation. Biochem. J. 353, 291-297 (2001).
29. Hill, C. R. Masters, E. I. & Whitby, F. G. The 11S regulators of 20S proteasome activity. Curr. Top. Microbiol. Immunol. 268, 73-89 (2002).
30. Whitby, F. G. et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408, 115-120 (2000).
31. Realini, C., Rogers, S. W. & Rechsteiner, M. KEKE motifs. Proposed roles in protein-protein association and presentation of peptides by MHC class I receptors. FEBS Lett. 348, 109-113 (1994).
32. Palmer, A. et al. Subpopulations of proteasomes in rat liver nuclei, microsomes and cytosol. Biochem. J. 316, 401-407 (1996).
33. Amsterdam, A., Pitzer, F. & Baumeister, W. Changes in intracellular localization of proteasomes in immortalized ovarian granulosa cells during mitosis associated with a role in cell cycle control. Proc. Natl Acad. Sci. USA 90. 99-103 (1993).
34. Palmer, A., Mason, G. G., Paramio, J. M., Knecht, E. & Rivett, A. J. Changes in proteasome localization during the cell cycle. Eur. J. Cell Biol. 64, 163-175 (1994).
35. Lafarga, M., Fernandez, R., Mayo, I., Berciano, M. T. & Castano, J. G. Proteasome dynamics during cell cycle in rat Schwann cells. Glia 38, 313-328 (2002).
36. Reits, E. A., Benham, A. M., Plougastel, B., Neefjes, J. & Trowsdale, J. Dynamics of proteasome distribution in living cells. EMBO J. 16, 6087-6094 (1997). This paper demonstrates the free and rapid diffusion of the vast majority (> 90%) of the proteasome within, but not between, the cytoplasmic and nuclear compartments of the cell, and how the cytoplasmically generated proteasome enteres the nucleus.
37. Wojcik, C. & DeMartino, G. N. Intracellular localization of proteasomes. Int. J. Biochem. Cell Biol. 35, 579-589 (2003).
38. Gordon, C. The intracellular localization of the proteasome. Curr. Top. Microbiol. Immunol. 268, 175-184 (2002).
39. Pickart, C. M. Ubiquitin enters the new millennium. Mol. Cell 8, 499-504 (2001).
40. Hicke, L. A new ticket for entry into budding vesicles-ubiquitin. Cell 106, 527-530 (2001).
41. Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins. Nature 426, 895-899 (2003).
42. Yang, Y. & Yu, X. Regulation of apoptosis: the ubiquitous way. FASEB J. 17, 790-799 (2003).
43. King, R. W., Deshaies, R. J., Peters, J. M. & Kirschner, M. W. How proteolysis drives the cell cycle. Science 274, 1652-1659 (1996).
44. Murray, A. W. Recycling the cell cycle: cyclins revisited. Cell 116, 221-234 (2004).
45. Glotzer, M., Murray, A. W. & Kirschner, M. W. Cyclin is degraded by the ubiquitin pathway. Nature 349, 132-138 (1991).
46. Diehl, J. A., Zindy, F. & Sherr, C. J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 11, 957-972 (1997).
47. Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M. & Roberts, J. M. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 10, 1979-1990 (1996).
48. Pagano, M. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685 (1995).
49. Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J. Biol. Chem. 274, 13886-13893 (1999).
50. Tam, S. W., Theodoras, A. M. & Pagano, M. Kip1 degradation via the ubiquitin-proteasome pathway. Leukemia 11(Suppl 3), 363-366 (1997).
51. Mailand, N. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425-1429 (2000).
52. Bernardi, R., Liebermann, D. A. & Hoffman, B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 19, 2447-2454 (2000).
53. Baldin, V., Cans, C., Knibiehler, M. & Ducommun, B. Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation. J. Biol. Chem. 272, 32731-32734 (1997).
54. Chen, F. et al. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc. Natl Acad. Sci. USA 99, 1990-1995 (2002).
55. Chène, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 3, 102-109 (2003).
56. Soussi, T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann. NY Acad. Sci. 910, 121-137 (2000).
57. Momand, J., Wu, H. H. & Dasgupta, G. MDM2-master regulator of the p53 tumor suppressor protein, Gene 242, 15-29 (2000).
58. Sherr, C. J. & Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10, 94-99 (2000).
59. Maki, C. G., Huibregtse, J. M. & Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56, 2649-2654 (1996).
60. Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997).
61. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
62. Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997).
63. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951 (2000).
64. Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301-310 (2002).
65. Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773-785 (1994).
66. Li, C. C., Dai, R. M. & Longo, D. L. Inactivation of NF-κB inhibitor IκBα: ubiquitin-dependent proteolysis and its degradation product. Biochem. Biophys. Res. Commun. 215, 292-301 (1995).
67. Adams, J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol. Med. 8, S49-S54 (2002).
68. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. & Baldwin, A. S. Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683 (1998). An early study demonstrating that proteasome inhibition induces apoptosis in proliferating (but not quiescent and differentiated) leukaemic cells in a manner that is associated with the activation of CPP32 and increased KIP1 levels.
69. Varfolomeev, E. E. et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 9, 267-276 (1998).
70. Drexler, H. C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl Acad. Sci. USA 94, 855-860 (1997).
71. Masdehors, P. et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br. J. Haematol. 105, 752-757 (1999).
72. Drexler, H. C., Risau, W. & Konerding, M. A. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 14, 65-77 (2000).
73. Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin. Cancer Res. 6, 916-923 (2000).
74. Bogner, C. et al. Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and-independent pathways. Exp. Hematol. 31, 218-225 (2003).
75. Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076 (2001).
76. Guzman, M. L. et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl Acad. Sci. USA 99, 16220-16225 (2002). This study shows the ability of proteasome inhibition to combine well with anthracycline therapy to targat leukaemic cells in vitro and in vivo, through NF-κB- and p53-related mechanisms.
77. Stirewalt, D. L. et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97, 3589-3595 (2001).
78. Schenkein, D. Proteasome inhibitors in the treatment of B-cell malignancies. Clin. Lymphoma 3, 49-55 (2002).
79. Masdehors, P. et al. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood 96, 269-274 (2000).
80. Kordes, U., Krappmann, D., Heissmeyer, V., Ludwig, W. D. & Scheidereit, C. Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14, 399-402 (2000).
81. Feinman, R. et al. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93, 3044-3052 (1999).
82. Ni, H. et al. Analysis of expression of nuclear factor κB (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis. Br. J. Haematol. 115, 279-286 (2001).
83. Jeremias, I. et al. Inhibition of nuclear factor κB activation attenuates apoptosis resistance in lymphoid cells. Blood 91, 4624-4631 (1998). This paper demonstrates that inhibition of NF-κB activity, either through proteasome inhibition or by mutant IκBα, increases the sensitivity of cells to apoptosis, including cells resistant to apoptosis, following treatment with various agents.
84. Bentires-Alj, M. et al. NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22, 90-97 (2003).
85. Adams, J., Palombella, V. J. & Elliott, P. J. Proteasome inhibition: a new strategy in cancer treatment. Invest. New Drugs 18, 109-121 (2000).
86. Almond, J. B. & Cohen, G. M. The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433-443 (2002).
87. Figueiredo-Pereira, M. E., Chen, W. E., Li, J. & Johdo, O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J. Biol. Chem. 271, 16455-16459 (1996).
88. Lum, R. T. et al. A new structural class of proteasome inhibitors that prevent NF-κB activation. Biochem. Pharmacol. 55, 1391-1397 (1998).
89. Lum, R. T. et al. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides. Bioorg. Med. Chem. Lett. 8, 209-214 (1998).
90. Wilk, S., Pereira, M. & Yu, B. Probing the specificity of the bovine pituitary multicatalytic proteinase complex by inhibitors, activators, and by chemical modification. Biomed. Biochim. Acta 50, 471-478 (1991).
91. Orlowski, M., Cardozo, C. & Michaud, C. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry 32, 1563-1572 (1993).
92. Meng, L., Kwok, B. H., Sin, N. & Crews, C. M. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res. 59, 2798-2801 (1999).
93. Kim, K. B., Myung, J., Sin, N. & Crews, C. M. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg. Med. Chem. Lett. 9, 3335-3340 (1999).
94. Bogyo, M. et al. Covalent modification of the active site threonine of proteasomal β subunits and the Escherichia coli homolog HSIV by a new class of inhibitors. Proc. Natl Acad. Sci. USA 94, 6629-6634 (1997).
95. Elliott, P. J., Zollner, T. M. & Bochncke, W.-H. Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med. 81, 235-245 (2003).
96. An, B., Goldfarb, R. H., Siman, R. & Dou, Q. P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5, 1062-1075 (1998).
97. Adams, J. et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. 8, 333-338 (1998).
98. Shah, I. M., Lees, K. R., Pien, C. P. & Eliott, P. J. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 54, 269-276 (2002).
99. Andre, P. et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl Acad. Sci. USA 95, 13120-13124 (1998).
100. Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622 (1999). A key paper describing the selection, characteristics, and early in vitro and in vivo studies of PS-341, later named bortezomib.
101. Dietrich, C., Bartsch, T., Schanz, F., Oesch, F. & Wieser, R. J. p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl Acad. Sci. USA 93, 10815-10819 (1996).
102. Lopes, U. G., Erhardt, P., Yao, R. & Cooper, G. M. p53-dependent induction of apoptosis by proteasome inhibitors. J. Biol. Chem. 272, 12893-12896 (1997).
103. Ling, Y. H. et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol. Cancer Ther. 1, 841-849 (2002).
104. Dou, Q. P., McGuire, T. F., Peng, Y. & An, B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J. Pharmacol. Exp. Ther. 289, 781-790 (1999).
105. Yu, C. L. & Burakoff, S. J. Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 stimulation. J. Biol. Chem. 272, 14017-14020 (1997).
106. Callus, B. A. & Mathey-Prevot, B. Interleukin-3-induced activation of the JAK/STAT pathway is prolonged by proteasome inhibitors. Blood 91, 3182-3192 (1998).
107. Pasquini, L. A., Paez, P. M., Moreno, M. A., Pasquini, J. M. & Soto, E. F. Inhibition of the proteasome by lactacystin enhances oligodendroglial cell differentiation. J. Neurosci. 23, 4635-4644 (2003).
108. Shah, S. A. et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 82, 110-122 (2001).
109. Russo, S. M. et al. Enhancement of radiosensity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. 50, 183-193 (2001). This paper demonstrates the ability of bortezomib to enhance the sensitivity of neoplastic cells to radiation therapy in vitro and in vivo in a manner that is associated with the inhibition of radiation-induced NF-κB activation.
110. Cusack, J. C. Jr. et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61, 3535-3540 (2001). A demonstration of the ability of bortezomib to act in combination with conventional chemotherapy in solid tumour cells in vitro and in vivo. This paper also demonstrates the ability of bortezomib to inhibit the NF-κB activation induced by SN-38.
111. Ma, M. H. et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9, 1136-1144 (2003).
112. Lenz, H. J. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat. Rev. 29(Suppl 1), 41-48 (2003).
113. Chauhan, D. et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 63, 6174-6177 (2003).
114. Chandra, J. et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92, 4220-4229 (1998).
115. Gatto, S. et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88, 853-863 (2003).
116. Hideshima, T. et al. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 277, 16639-16647 (2002).
117. Mitsiades, N. et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl Acad. Sci. USA 99, 14374-14379 (2002).
118. Hideshima, T. et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101, 1530-1534 (2003).
119. LeBlanc, R. et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62, 4996-5000 (2002).
120. Sunwoo, J. B. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7, 1419-1428 (2001).
121. Teicher, B. A., Ara, G., Herbst, R., Palombella, V. J. & Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638-2645 (1999).
122. Wang, C. Y., Cusack, J. C. J., Liu, R. & Baldwin, A. S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nature Med. 5, 412-417 (1999).
123. Mitsiades, N. et al. The proteasome inhibitor PS-341 potentiates sensitvity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380 (2003). This paper demonstrates the synergistic activity of bortezomib used in combination with DNA-damaging agents in multiple myeloma cells, as well as the ability of bortezomib to remove cell-adhesion-mediated drug resistance. Bortezomib is also shown to downregulate multiple DNA-repair proteins.
124. Bold, R. J., Virudachalam, S. & McConkey, D. J. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. 100, 11-17 (2001).
125. Aghajanian, C. et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Pes. 8, 2505-2511 (2002).
126. Orlowski, R. Z. et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 20, 4420-4427 (2002). One of two key Phase I clinical trials of bortezomib. This was a dose-ranging study in patients with advanced haematological malignancies, including multiple myeloma. The study demonstrated patient responses and acceptable toxicities and, in conjunction with reference 125, helped define the dose for the Phase II trials.
127. Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003). The key Phase II trial that led to the approval of the first proteasome inhibitor for the treatment of patients with multiple myeloma.
128. Read, M. A. et al. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2, 493-506 (1995).
129. Nefedova, Y., Landowski, T. H. & Dalton, W. S. Bone marrow stromal-dedved soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 17, 1175-1182 (2003).
130. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A. & Dalton, W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93, 1658-1667 (1999).
131. Grigorieva, I., Thomas, X. & Epstein, J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp. Hematol. 26, 597-603 (1998).
132. Vacca, A. et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064-3073 (1999).
133. Oikawa, T. et al. The proteasome is involved in angiogenesis. Biochem. Biophys. Res. Commun. 246, 243-248 (1998).
134. Mezquita, J., Mezquita, B., Pau, M. & Mezquita, C. Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J. Cell Biochem. 89, 1138-1147 (2003).
135. Bladé, J. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 102, 1115-1123 (1998).
136. Berenson, J. R. et al. Experience with long-term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM). Proc. Am. Soc. Clin. Oncol. 22, 710 (2003).
137. Odowski, R. Z. et al. Phase I study of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with refractory hematologic malignancies. Blood 102, 449a (2003).
138. Yang, H. H. et al. A phase I/II trial of VELCADE™ and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myeloma (MM). Blood 102, 235a (2004).
139. Richardson, P. G. et al. Peripheral neuropathy following bortezomib (VELCADE™, formedy PS-341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. Blood 102, 149a (2003).